Interview with: John C. Hertig, Chairman, President and CEO - featuring: their proprietary products including venous vessel introducers, articulating and fixed curve delivery catheters, epicardial and endocardial stimulation leads, and other products for use in pacemaker, defibrillator, catheter and infusion port procedures as well as neuromdulation markets. |
|
| Enpath Medical, Inc.
(NPTH-NASDAQ) |
|
|
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
This is a printer friendly page! Enpath Medical’s
mission is to solve problems for their customers by becoming an extension of their OEM
partners in both the R&D and manufacturing of blood vessel Introducers, steerable
catheters and stimulation leads for numerous therapies and implantable devices such as
pacemakers, defibrillators and catheters
|
|
| “We incubate, develop and, at times, commercialize novel and proprietary technology that enables the delivery of new therapies. There isn’t a company comparable to Enpath out there. Our customers are developing cutting-edge therapies that are predicated on our technology. As a result, we have steady interest in our products and capabilities driven equally by high-growth new market opportunities such as neurostimulation, and steady, predictable growth of large, established market opportunities like the ICD industry. In specific reference to our products, we are the best in the world at creating introducers. Introducers are a basic building block of interventional medical device therapy, widely used and highly important. Regarding catheters, we have been making these for a long time and we are very efficient and good at developing new them. If you combine Introducers, Steerable Catheters and Stimulation Leads together, then the investor sees a company that has unique capabilities, that is focused on developing products that have imbedded intellectual property in order to ensure they can maintain margins or increase margins and revenue growth. We can grow a lot faster than the markets that we currently serve today due to our new product development capabilities.” - John C. Hertig | |
